Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xofluza for Influenza in Pediatric Transplant Recipients with Wearable Alerting
NCT06161454Phase 4Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of baloxavir marboxil in influenza (4 arms), sponsored by Children's Hospital of Philadelphia. Primary endpoints: Time-to-Clinical-Response at 30 days and Incidence of complicated hospital stay(s) at 30 days. Started Dec 2023; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06161454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161454.